Loading…
Employees: 3,515
Size Shandong Jincheng Pharmaceutical (300233.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $661M, the 3209th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.67 on 6 Nov 2026.
Performance Over six months the shares fell 24.8%, against -8.8% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 2.2% over the last twelve months (peer median +10.2%); the operating margin is 4.4% (peer median 7.0%).
Valuation It trades at 1.4× enterprise value to sales against a peer median of 2.6× (4th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.2 points above its cost of capital (8.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.83B | CN¥2.72B | CN¥3.35B | CN¥3.52B | CN¥3.49B |
| Revenue growth | — | -19% | -5% | +1% | — |
| Gross profit | CN¥1.14B | CN¥850M | CN¥1.21B | CN¥1.43B | CN¥1.50B |
| EBITDA | n/a | CN¥408M | CN¥575M | CN¥516M | CN¥630M |
| Net income | CN¥157M | CN¥44.2M | CN¥197M | CN¥175M | CN¥273M |
| Free cash flow | CN¥316M | CN¥220M | CN¥154M | CN¥323M | -CN¥118M |
| Capital expenditure | CN¥90.5M | CN¥101M | CN¥143M | CN¥343M | CN¥374M |
| Total debt | CN¥365M | CN¥533M | CN¥658M | CN¥820M | CN¥849M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300233.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.6% | -5.4% | 6th lowest of 21 |
| 6-month return | -24.8% | -8.8% | 6th lowest of 21 |
| Distance from 52-week high | -35.8% | -31.9% | 9th lowest of 21 |
| Revenue growth (TTM) | +2.2% | +10.2% | 6th lowest of 18 |
| Operating margin | 4.4% | 7.0% | 7th lowest of 18 |
| EV / Sales | 1.4× | 2.6× | 4th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 1.1% | 6.2% | 6th least demanding of 11 |
| Growth delivered (Del g) | -1.6% | +8.4% | 4th lowest of 11 |
| Hurdle (Req g minus delivered) | +2.7 pp | +8.4 pp | 6th least demanding of 11 |
| ROIC minus cost of capital | +0.2 pp | -4.0 pp | 7th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | 1.4× | 1.1% | -1.6% |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 5.1× | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | 2.2× | 0.3% | -17.9% |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | 2.6× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 2.9× | 23.2% | +21.9% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | 19.0× | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | 2.5× | 12.1% | -5.9% |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | 107.7× | n/a | n/a |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | 2.5× | 25.9% | +10.3% |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | 13.6× | 50.8% | +16.2% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 2.5× | -2.4% | +6.4% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 0.6× | -2.5% | -1.8% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | 6.2× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 0.7× | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 1.0× | -4.9% | +6.5% |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 10.9× | 41.4% | +11.2% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 2.5× | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 3.4× | 0.0% | +51.6% |